Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dragenopharm (officially Dragenopharm Apotheker Püschl GmbH) is a German contract development and manufacturing organization (CDMO) specializing in solid dosage forms, including tablets, film-coated tablets, sugar-coated tablets, and hard shell capsules. Founded in 1949 and headquartered in Tittmoning, Germany, the company merged with Swiss Caps in 2008 to form the Aenova Group, one of the world's leading pharmaceutical CDMOs. Dragenopharm operates as a key high-volume manufacturing site within the Aenova network, producing prescription drugs, over-the-counter (OTC) medicines, and dietary supplements. Its state-of-the-art facility in Tittmoning is one of Europe's largest production plants for oral solids, with capabilities extending to controlled-release products, narcotics, and packaging services.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dragenopharm.